@FiercePharma: Medtronic settles DoJ charges for $4.1M on spinal device sales in Malaysia, China. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: Layoffs for manufacturing units at Amgen, Novartis contributed to sizable cuts last year. Check out the new feature | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals. Report | Follow @CarlyHFierce
> Amgen's ($AMGN) colon cancer drug Vectibix won broader approval in Europe, as a first-line treatment in certain patients, in combination with a chemotherapy regimen called FOLFIRI. Report
> Mylan ($MYL) rolled out its version of Generess Fe, a contraceptive brand marketed by Warner Chilcott; it's the first generic form of the product. Report
> AbbVie ($ABBV) asked a U.S. judge to dismiss claims by Shire ($SHPG) shareholders, who say the Illinois-based company misrepresented the importance of tax incentives in its aborted agreement to buy Shire. Report
> A U.S. judge tossed out one the few remaining thalidomide cases against GlaxoSmithKline ($GSK), Legal Intelligencer reports. Article
> Roche's ($RHHBY) Rituxan, approved to treat blood cancers and rheumatoid arthritis, could be a treatment option for a rare disease known as eosinophilic granulomatosis and polyangiitis (EGPA), a study found. Report
Medical Device News
@FierceMedDev: Check out the top med tech companies of 2014. Feature | Follow @FierceMedDev
@VarunSaxena2: Experts: Stent retrieval devices to play larger role in treatment of stroke. Story | Follow @VarunSaxena2
@EmilyWFierce: Natera ropes in $55M with eye on cancer Dx. FierceDiagnostics article | Follow @EmilyWFierce
> Miniaturized skin cancer device emerges as alternative to surgery. Article
> J&J's Ethicon gets FDA clearance to use Evarrest patch for liver surgery. Report
Biotech News
@FierceBiotech: High-flying immuno-oncology player Adaptimmune pitches $150M IPO. News | Follow @FierceBiotech
@JohnCFierce: Plotting a course for True North, biotech CEO steps up with a $35M round. Report | Follow @JohnCFierce
> CRISPR-Cas9 pioneer starts recruiting R&D group in Cambridge hub. More
> Merck wagers $434M on Arvinas and its protein-disposal system. Report
> Ocular Therapeutix plunges as eye treatment blurs the line in PhIII. Article
> Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. News
Drug Delivery News
> Gold nanoparticles deliver RNA to the brain to suppress cancer genes. Story
> Developer of Botox lotion files for $58M IPO. Item
> Researchers take aim at childhood neuroblastoma with targeted nanoparticles. More
> Actavis' drug delivery-focused spinoff on the prowl for acquisitions. Report
> AstraZeneca gets FDA nod for alternative administration of oral heart med. Article
Pharma Manufacturing News
> AMRI moves forward with plan to close Wales API plant, cut 62 jobs. Item
> Baxter recalls more than half a million units of saline. News
> North Carolina compounder is closed and its products are recalled. Story
> India's Mankind Pharma investing $16M in API plant. Article
> UAE drug distributor building a $20M plant in Dubai. Report
Pharma Asia News
> Australia-China researchers eye Asian stroke drug for Alzheimer's disease. Story
> South Korea struggles with healthcare needs of elderly. Report
> Second quarter pharma market outlooks for pan-Asia mixed, India promising. Story
> India's Mankind sees 15th product plant online this year. Article
> Sirtex Medical oncology play still has some thunder Down Under. More
And Finally... The "Baron of Botox," dermatologist Dr. Fredric Brandt, died Sunday at his Florida home; police say he committed suicide. Report